Suggestions

Du même auteur

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

Archive ouverte | Harter, P. | CCSD

International audience. The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) i...

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Archive ouverte | Lorusso, Domenica | CCSD

International audience. Objective In the PAOLA-1/ENGOT-ov25 trial ( NCT02477644 ), adding maintenance olaparib to bevacizumab provided a substantial progression-free survival benefit in patients with newly diagnosed...

GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles

Archive ouverte | Pozzorini, Christian | CCSD

International audience. Homologous recombination deficiency (HRD) is a predictive biomarker for poly(ADP-ribose) polymerase 1 inhibitor (PARPi) sensitivity. Routine HRD testing relies on identifying BRCA mutations, ...

Chargement des enrichissements...